Brooks Laboratories Analysis

dividend

Pros

Cons

• Unable to calculate sustainability of dividends as Brooks Laboratories has not reported any payouts.
• Unable to evaluate Brooks Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Brooks Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• Debt is covered by short term assets, assets are 1.2x debt.
• Brooks Laboratories's cash and other short term assets cover its long term commitments.
• Brooks Laboratories's level of debt (29.4%) compared to net worth is satisfactory (less than 40%).

Cons

• Brooks Laboratories's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
• Operating cash flow is negative therefore debt is not well covered.
• The level of debt compared to net worth has increased over the past 5 years (1.2% vs 29.4% today).
• High level of physical assets or inventory.

management

Pros

• The tenure for the Brooks Laboratories board of directors is about average.
• Rajesh's remuneration is lower than average for companies of similar size in India.
• Rajesh's compensation has been consistent with company performance over the past year, both up more than 20%.
• The tenure for the Brooks Laboratories management team is about average.

Cons

misc

Pros

Cons

• Brooks Laboratories is not covered by any analysts.
• Brooks Laboratories has significant price volatility in the past 3 months.

past

Pros

Cons

• Unable to compare Brooks Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.
• Brooks Laboratories does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
• It is difficult to establish if Brooks Laboratories has efficiently used its assets last year compared to the IN Life Sciences industry average (Return on Assets) as it is loss-making.
• It is difficult to establish if Brooks Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
• It is difficult to establish if Brooks Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
• Unable to compare Brooks Laboratories's 1-year growth to the IN Life Sciences industry average as it is not currently profitable.

value

Pros

• Brooks Laboratories is good value based on assets compared to the IN Life Sciences industry average.
• NSEI:BROOKS is up 6.5% outperforming the Life Sciences industry which returned 2.6% over the past month.

Cons

• Brooks Laboratories is loss making, we can't compare its value to the IN Life Sciences industry average.
• Brooks Laboratories is loss making, we can't compare the value of its earnings to the India market.
• BROOKS underperformed the Life Sciences industry which returned 36.1% over the past year.
• BROOKS underperformed the Market in India which returned -14.5% over the past year.
• NSEI:BROOKS is up 6.5% underperforming the market in India which returned 8% over the past month.